Table 2A. Clinical and pathological variables associated with tumor upstaging and upgrading. CIPC: cancer involvement in positive cores.
| Upstaging | Upgrading | |||||
|---|---|---|---|---|---|---|
| No (n=272) | Yes (n=66) | p-value | No (n=192) | Yes (n=146) | p-value | |
| Age (years) | 63.5 [59 ; 67] | 63.5 [58.75 ; 66] | 0.918 | 63 [58 ; 67] | 64 [59.75 ; 67] | 0.176 |
| PSA (ng/mL) | 5.68 [4.35 ; 7.3] | 5.6 [4.12 ; 6.68] | 0.584 | 5.55 [4.2 ; 7.3] | 5.6 [4.43 ; 7.09] | 0.834 |
| PSA density | 0.12 [0.09 ; 0.15] | 0.12 [0.09 ; 0.15] | 0.716 | 0.12 [0.09 ; 0.15] | 0.12 [0.09 ; 0.15] | 0.468 |
| Prostate Volume | 48 [40 ; 55] | 49.5 [41 ; 54.25] | 0.728 | 49 [41 ; 55] | 48.5 [40 ; 55] | 0.681 |
| Familiarity, Yes | 16 (5.9) | 5 (7.6) | 0.576 | 12 (6.3) | 9 (6.2) | 0.974 |
| PNI. Yes | 13 (4.8) | 7 (10.6) | 0.083 | 7 (3.6) | 13 (8.9) | 0.042 |
| Nr of Positive Cores, 2 | 122 (44.9) | 38 (57.6) | 0.063 | 86 (44.8) | 74 (50.7) | 0.282 |
| CIPC (%) | 20 [10 ; 30] | 40 [30 ; 50] | <0.001 | 20 [10 ; 30] | 30 [20 ; 45] | <0.001 |
| Positive DRE | 26 (9.6) | 10 (15.2) | 0.186 | 18 (9.4) | 18 (12.3) | 0.477 |
| Testosterone (ng/dL) | 488.5 [401 ; 600] | 299.5 [250 ; 390] | <0.001 | 497.5 [401 ; 600] | 400.5 [292.25 ; 534] | <0.001 |
| Testosterone <300 ng/dL | 20 (7.4) | 33 (50) | <0.001 | 13 (6.8) | 40 (27.4) | <0.001 |
DRE: Digital rectal examination; PNI: perineural invasion; PSA: prostate-specific antigen